ITLN2

Across TCGA pan-cancer cohorts, ITLN2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ITLN2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ITLN2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ITLN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC and LUAD are the cancer types where ITLN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.959	0.765	.003	24	view →
LUAD	OS	Median	All	0.471	0.791	.015	13	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ITLN2–PDAC (OS)

Open the PDAC breakdown →